{"filing":{"accession_number":"0001493152-26-035553","cik":"0001692415","ticker":"CODX","company_name":"Co-Diagnostics, Inc.","form":"8-K","filing_date":"2026-07-31","report_date":"2026-07-30","primary_document":"form8-k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1692415/000149315226035553/form8-k.htm"},"events":[{"id":22860,"run_id":20693,"accession_number":"0001493152-26-035553","anchor_item_number":null,"event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.92,"summary":"Co-Diagnostics entered into an inducement agreement on July 30, 2026, whereby warrant holders exercised existing warrants for approximately $2.67 million in gross proceeds, and the Company issued new warrants to purchase 3,404,724 additional shares at $1.56 per share. This is a dilutive equity issuance structured as a warrant exchange that increases outstanding shares from 5,277,846 to 6,980,208 (32% dilution) and requires future stockholder approval. The transaction is material to investors as it substantially dilutes existing shareholders and raises capital through equity rather than debt.","company_name":"Co-Diagnostics, Inc.","ticker":"CODX","filing_date":"2026-07-31","form":"8-K","submitted_at":null,"items":null}],"classifications":[{"id":22938,"accession_number":"0001493152-26-035553","item_number":null,"item_title":null,"event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.92,"reasoning":"Co-Diagnostics entered into an inducement agreement on July 30, 2026, whereby warrant holders exercised existing warrants for approximately $2.67 million in gross proceeds, and the Company issued new warrants to purchase 3,404,724 additional shares at $1.56 per share. This is a dilutive equity issuance structured as a warrant exchange that increases outstanding shares from 5,277,846 to 6,980,208 (32% dilution) and requires future stockholder approval. The transaction is material to investors as it substantially dilutes existing shareholders and raises capital through equity rather than debt.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-02T02:34:54.094864+00:00","company_name":"Co-Diagnostics, Inc.","ticker":"CODX","filing_date":"2026-07-31"}]}